JANUARY 14
  • SYMPOSIUM

    13th International
    symposium on MPS and
    related diseases

    2014.08.05 ~ 09 Bahia, Brazil
  • SYMPOSIUM

    13th International
    symposium on MPS and
    related diseases

    2014.08.05 ~ 09 Bahia, Brazil
  • SYMPOSIUM

    13th International
    symposium on MPS and
    related diseases

    2014.08.05 ~ 09 Bahia, Brazil
  • SYMPOSIUM

    13th International
    symposium on MPS and
    related diseases

    2014.08.05 ~ 09 Bahia, Brazil

About Us

  1. Who We Are
  2. History
  3. Founder
  4. Board of Directors
  • Identity
    Helping
    patients and
    society
    by developing new

    treatments
    Generating value
    with science
    and
    open innovation

    Mogam Culture code

    Who We Are
    • Non-profit research institute

      Korea's first privately-funded non-profit research institute

      Helping society through the development of life science technology

      Creation of a continuous research environment

    • Achievements through research activities

      Developing the world's 3rd hepatitis B vaccine

      Developing the world's 1st vaccine for hemorrhagic fever with renal syndrome (HFRS)

      Developing the world's 2nd varicella vaccine

    • Development of innovative new drugs

      Developing treatments and vaccines for rare diseases, autoimmune diseases, infectious
      diseases, cancers, etc.

      Developing new drugs and establishing platforms through open innovation

      Pursuing the goals of developing new drugs and improving public health on a global scale

  • History of MOGAM

    Based on scientific identification and
    understanding of life phenomena, we are
    constantly
    striving to leap into a research
    center equipped with new drug development
    capabilities

    1. View of the former MOGAM Institute for Biomedical Research
    2. The MOGAM Institute for Biomedical Research (MIBR), Korea’s first privately owned non-profit research institute, was established in 1984 by Dr. Young-sup Huh using all of the profit generated from the successful development of the Hepatitis B vaccine by Green Cross Pharmaceuticals.

      MIBR has made significant contributions to Korea’s biomedical industry by successfully producing vaccines, diagnostic kits, and important recombinant proteins. MIBR led to the development of the third in the world Hepatitis B vaccine, the first Epidemic hemorrhagic fever vaccine, and the second chickenpox vaccine.

      View of the former R&D center

    1. The 30th anniversary of
      MOGAM Institute of Biomedical Research
    2. Became a WHO-designated Collaborating Research Center
    1. Our mission is to help those suffering from disease by understanding life’s underlying cellular and molecular processes and using this knowledge to develop innovative therapies.

      The MIBR is the place for creative thought and collaboration to bridge between academic institutions and industry.

    2. View of current R&D center
    Timeline
    • Rising Up

      Seeking to become a global powerhouse for drug discovery

      • 2020
      • 2020.03

        Obtained NDA approval of new varicella vaccine (Barycela)

        2020.02

        Dr.Jae Uk Jeong became the 10th Director/President of the MIBR

      • 2018
      • 2018.09

        Dr.Eui-Cheol Jo became the 9th Director/President of the MIBR

      • 2016
      • 2016.05

        The Name was changed to MOGAM Institute for Biomedical Research(MIBR)

      • 2015
      • 2015.12

        Obtained NDA approval of Avian Influenza(AI) virus vaccine

        2015.11

        Obtained NDA approval of Quadrivalent flu vaccine

        2015.03

        Awarded 16th New Drug Technology of Korea (NeulaPEG)

        2015.02

        Dr.Senyon Choe became the 8th Director/President of the MBRI

    • Maturity

      Seeking to become a global powerhouse for drug discovery

      • 2013
      • 2013.05

        Phase II IND approval for Avian Influenza (AI) virus vaccine

        2013.04

        Dr.Eun-Chul Huh became the 7th Director/President of the MBRI

      • 2011
      • 2011.12

        Korean IND approved for phase II/III in Neutropenia

      • 2010
      • 2010.06

        Korean IND approved for an anti-angiogenic cancer drug

        2010.03

        Korean IND approved for natural killer (NK) cell therapy

      • 2009
      • 2009.12

        Minister Award at the Health Industry Technology Awards (for the anti-angiogenic cancer drug)

        2009.09

        Korean IND approved for an Avian Influenza (AI) vaccine

        2009.07

        U.S. IND approved for the anti-angiogenic cancer drug

      • 2008
      • 2008.09

        Korean IND approved for the neutropenia drug

        2008.05

        Dr. Yeup Yoon became the 6th Director of the MBRI

      • 2005
      • 2005.12

        Collaboration with the U.S. MD Anderson Cancer Center

        2005.03

        Redesignation of WHO Collaborating Research Center (for vaccines and diagnostic reagents)

      • 2004
      • 2004.10

        MOU with German Fraunhofer-IME for joint research

        2004.03

        Developed a diagnostic reagent for SARS

    • Growth

      Seeking to become a global powerhouse for drug discovery

      • 2003
      • 2003.11

        Signed an agreement with the Chinese ICDC to conduct joint research into diagnostic reagents

        2003.04

        Established cord blood storage technology

      • 2001
      • 2001.07

        Built and started to run a bio pilot plant

      • 2000
      • 2000.11

        Dr. Du-hong Park became the 5th Director of the MBRI

      • 1996
      • 1996.10

        Dr. Su-il Jeong became the 4th Director of the MBRI

      • 1995
      • 1995.02

        Redesignation of WHO Collaborating Research Center (for vaccines and diagnostic reagents)

      • 1994
      • 1994.10

        Established the Mogam Biotechnology Award sat the Korean Society for Molecular Biology

    • Beginning

      Seeking to become a global powerhouse for drug discovery

      • 1993
      • 1993.06

        Developed the world's 2nd varicella vaccine (Suduvax)

      • 1992
      • 1992.05

        Dr. Hong-mo Moon became the 3rd Director of the MBRI

      • 1991
      • 1991.11

        Developed the world's 1st vaccine for Epidemic hemorrhagic fever (Hantavax)

      • 1990
      • 1990.08

        Developed an AIDS (HIV-1) diagnostic reagent

      • 1989
      • 1989.12

        First designation of WHO Collaborating Research Center (for vaccines and diagnostic reagents)

        1989.05

        Dr. Seung-bok Baek became the 2nd Director of the MBRI

      • 1985
      • 1985.12

        Renamed the MOGAM Biotechnology Research Institute (MBRI)

        1985.02

        Selected as a military research institute

      • 1984
      • 1984.05

        Dr.Gyeong-ho Kim became the 1st Director of the institute

        1984.05

        Established as the Green Cross Research Foundation, the nation's first non-profit research institute approved by the Ministry of Science and Technology

  • Founder

    Dr. Mogam Young-sup Huh

    1. Young-sup Huh Dr. Mogam Young-sup Huh (Founder)
    2. “Even when the dust piles up,
      we must let it pile up on our soil...”

      The first President Dr. Mogam Young-sup Huh was a pioneer in the localization of essential medicines. He devoted his life to the development of novel drugs beneficial to the health of the people, rather than focusing on making a profit.


      Dr. Huh had been deeply concerned about the health environment in Korea while studying in Germany in the 1960s. After returning to Korea in 1970, he established Green Cross (currently GC Pharmaceuticals) and strived to localize essential medicines that had been imported from foreign countries. He laid the foundation for life science research with funds raised through the successful development of drugs such as a hepatitis B vaccine. He also founded today’s MOGAM Institute for Biomedical Research, a private research foundation, to contribute to the promotion of national science and technology and give back to society.


      “Even when the dust piles up, we must let it pile up on our soil...”

      These were the first President Dr. Mogam Young-sup Huh’s words with his philosophy that, even if the situation may be harsh, research achievements and manpower will remain in the country only when research institutes are established in Korea.


      Young-sup Huh Dr. Mogam Young-sup Huh (Founder)
    Mogam

    The first President Dr. Young-sup Huh's pen name which means enriching the Earth

    1. As a CEO who completed a Ph.D. course at RWTH Aachen University in Germany, Dr. Huh successfully led the company, pioneering the biotechnology industry in Korea, which had been previously unexplored. He made a number of contributions to promoting friendly cooperation between Korea and Germany through activities among private diplomatic organizations. This was recognized by his receiving the “Ehren senator” title, the most honorable title that RWTH Aachen University in Germany can confer, as a foreigner for the first time since the school's opening.

      Also, Dr. Huh did not hesitate to support Korean students and research foundations in Korea. When he heard the news from RWTH Aachen University in Germany, which is often referred to as the “European MIT,” that there were not enough reading rooms where students could study freely, he established "MOGAM Haus" in 2007 with his personal donation of EUR 1 million. Dr. Mogam Young-sup Huh, who passed away in 2009 at the age of 68, set a social example until the very end of his life by donating two-thirds of his stock and legacy to scholarship and research foundations.

      Dr. Huh devoted his life to creating a sustainable biopharmaceutical industry for the benefit of the Korean people. He was an excellent CEO in the biopharmaceutical field and an entrepreneur who always emphasized corporate social responsibility. The achievements of Dr. Mogam Young-sup Huh are of great significance in the improvement of the lives of people around the world, and across borders.

    Biography

      • 2007
      • Chairman of the Korean-German Chamber of Commerce and Industry (2007 - 2009)

        Donation for the MOGAM Haus at RWTH Aachen University in Germany

      • 2005
      • Chairman of the Korea Support Committee (KSC) of the International Vaccine Institute (IVI) (2005 - 2008)

      • 2003
      • 4th Chairman of the Korea Industrial Technology Association (KOITA) (2003 - 2008)

      • 2002
      • Awarded with Ehren Senator by RWTH Aachen University in Germany

      • 2001
      • Vice-chairman of the Federation of Korean Industries (2001 - 2009)

      • 2000
      • President of the Koreanisch-Deutsche Gesellschaft (KDG, Korean-German Association) (2000 - 2009)

      • 1997
      • 16th President of the Korea Pharmacy Association (1997 - 1999)

      • 1994
      • First Chairman of the Korea Organism Industry Association (1994 - 1997)

      • 1992
      • President and CEO of GC Pharma (1992 - 2009)

      • 1987
      • Chairman of the Korea Genetic Engineering Research Association (1987 - 1994)

      • 1984
      • Chairman of the MOGAM Institute for Biomedical Research (1984 - 2009)

      • 1980
      • President and CEO of GC Pharma

      • 1970
      • Joined GC Pharma

      • 2001
      • Obtained an Honorary Doctorate in Engineering from Hanyang University

      • 1970
      • Completed a Ph.D. course at RWTH Aachen University, Germany

      • 1968
      • Diploma at RWTH Aachen University, Germany

      • 1964
      • B.S., College of Engineering, Seoul National University

      • 2009
      • Received the Order of Science and Technology Merit, Creation Medal

      • 2008
      • Received the 22nd Inchon Award

      • 2005
      • Received the Distinguished Service Cross in Germany

      • 2002
      • Won the Korean CEO Grand Prize

      • 1992
      • Received the Order of Civil Merit, Peony Medal

      • 1984
      • Received the Silver Tower Order of Industrial Service Merit

      • 1982
      • Received the Stone Tower Order of Industrial Service Merit

  • Board of Directors

    The Board of Directors is proven leaders in
    business and non-profit communities. They are
    committed to
    the MIBR’s mission and bring a range
    of skills and perspectives in cutting-edge research
    and innovation.

    • Il-Sup Huh Chairman, Board
    • Doo-Hong Park Director, Board
    • DongJip Kim Director, Board
    • Ik-Lae Kim Auditor, Board
    • InSoon Han Director, Board
    • KwangSoon Shin Director, Board
    • HoWang Lee Director, Board
    • YungBog Chae Director, Board
    • ChanHee Lee Director, Board
    • EunChul Huh Director, Board
    • YungJue Bang Director, Board